The Zacks Analyst Blog Highlights: Mylan, Abbott Laboratories, Ista Pharmaceuticals, Johnson & Johnson and Teva Pharmaceuticals

For Immediate Release

Chicago, IL – May 27, 2011 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Mylan Inc. (MYL - Analyst Report), Abbott Laboratories (ABT - Analyst Report), Ista Pharmaceuticals Inc (ISTA - Snapshot Report), Johnson & Johnson (JNJ - Analyst Report) and Teva Pharmaceuticals (TEVA - Analyst Report).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Thursday’s Analyst Blog:

Mylan Launches New Generics

Mylan Inc.’s (MYL - Analyst Report) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals.

The product recorded sales of $325 million in US for the twelve months endied March 31, 2011 according to data released by IMS Health.

We note that the launch of the generic version of the pain reliever is the latest in the series of generic launches at Mylan. A couple of days ago the company, which is one of the largest generic and specialty pharmaceutical companies across the globe, launched its generic version of Abbott Laboratories’ (ABT - Analyst Report) Depakote Sprinkle Capsules for treating seizures.

The product recorded sales of $89 million in US for the twelve months ended March 31, 2011 according to data released by IMS Health.

Mylan had also recently launched the generic versions of Ista Pharmaceuticals Inc’s (ISTA - Snapshot Report) Xibrom ophthalmic solution and Johnson & Johnson’s (JNJ - Analyst Report) schizophrenia drug Risperdal.

The generic segment which develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule or transdermal patch forms, accounts for the bulk of the revenues at Mylan. Management stated that it currently has167 abbreviated new drug applications (ANDAs) pending approval by the US Food and Drug Administration (FDA) targeting $100.3 billion in branded sales.

Mylan believes that approximately 45 of the pending ANDAs are first-to-file opportunities and represent a market opportunity in excess of $25.8 billion (in terms of branded sales).

Our Recommendation

We currently have a Neutral recommendation on Mylan. The company carries a Zacks #3 Rank (Hold rating) in the short-run. Mylan is one of the leading players in the US generics market.

The company holds immense potential as many blockbuster drugs are slated to lose patent exclusivity in the forthcoming period. We are encouraged by Mylan’s robust generic product pipeline.

However, competition in the generic segment is strong with players like Teva Pharmaceuticals (TEVA - Analyst Report) in the field. We also remain concerned about the lack of growth in the European generics business. We intend to remain watchful until we get better visibility on top-line growth prospects in Europe.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Read the full analyst report on MYL

Read the full analyst report on ABT

Read the full analyst report on ISTA

Read the full analyst report on JNJ

Read the full analyst report on TEVA